Cannvas MedTech (CSE:MTEC) , a leading business technology company in the cannabis space, is pleased to announce the formation of Cannvas Cannabis Acquisitions Corp., a wholly-owned subsidiary with a focus on investment and acquisition in the expanding global cannabis sector.

“The North American cannabis market has emerged as an economic force and there are many investment opportunities that support this important sector,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “With the legalization of cannabis only weeks away, we are positioning our Company to leverage our broad network and extensive knowledge of the sector to take action when opportunities present themselves. Technology is the most obvious business where we will focus our attention, but because ancillary businesses and verticals are growing at unprecedented rates there are numerous opportunities that look interesting.”


Cannvas Cannabis Acquisitions seeks to complement Cannvas’ current product offering through continuous development, strategic investments and acquisitions in the cannabis sector. Related companies may include, but are not limited to:

  • Technology
  • Marketing and design
  • Packaging
  • Food and nutraceuticals
  • Regulation and enforcement
  • New product development
  • Cultivation related equipment
  • Gear and paraphernalia
  • Retail stores & dispensaries
  • Testing labs

Cannabis research sources calculate legal pot sales in North America climbed approximately 33% in 2017 to almost $10 billion, and project annual sales will grow to $25 billion by 2021. In a 2017 study, Deloitte estimates the size of the ancillary cannabis market to be approximately 2.5 times the size of the actual cannabis cultivation market.

About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

For further information: www.cannvasmedtech.com; Media Inquiries: media@cannvasmedtech.com; Investor Relations: ir@cannvasmedtech.com; 1-800-489-0116

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation. 

Source: www.newswire.ca

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less